OncLive TV

Dana Chase, MD, gynecologic oncologist, Arizona Oncology, discusses the presentation of uterine sarcomas.

Mark G. Kris, MD, William and Joy Ruane Chair in Thoracic Oncology, Memorial Sloan Kettering Cancer Center, discusses the use of chemotherapy in patients with non–small cell lung cancer (NSCLC).

Matthew D. Hellmann, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the role tumor mutational burden (TMB) plays in determining combination therapies for patients with non–small cell lung cancer (NSCLC).

Alexander Drilon, MD, clinical director, Early Drug Development Service, Memorial Sloan Kettering Cancer Center, discusses targeted agents for patients with ROS1-rearranged lung cancer.

Charles M. Rudin, MD, PhD, chief, Thoracic Oncology Service, co-director, Druckenmiller Center for Lung Cancer Research, Sylvia Hassenfeld Chair in Lung Cancer Research, Memorial Sloan Kettering Cancer Center, discusses the caveats of KEYNOTE-021.

Jeanne M. Palmer, MD, hematologist oncologist, Mayo Clinic, discusses molecular abnormalities in myeloproliferative diseases, including polycythemia vera (PV) and the use of next-generation sequencing in identifying these mutations.

Lyndsay J. Willmott, MD, gynecologic oncologist, Arizona Oncology, discusses the mechanisms of resistance to PARP inhibitors that have been identified in ovarian cancer.

Rana R. McKay, MD, assistant professor of medicine and medical oncologist at the University of California, San Diego, discusses the FDA approval of nivolumab (Opdivo) combined with ipilimumab (Yervoy) in patients with renal cell carcinoma (RCC).

Ruben Mesa, MD, director, The Mays Cancer Center, the newly named center of UT Health San Antonio MD Anderson Cancer Center, discusses the management of patients with myeloproliferative neoplasms.

James B. Yu, MD, associate professor, therapeutic oncology, director, Prostate and Genitourinary Cancer Radiotherapy Program, Yale Cancer Center, discusses the importance of a genetic counselor in the treatment of patients with prostate cancer.

Robert Andtbacka, MD, associate professor in the Division of Surgical Oncology, Department of Surgery at the University of Utah School of Medicine, discusses the future of talimogene laherparapvec (T-VEC; Imlygic) in the treatment of patients with melanoma.

Keith Stewart, MB, CHB, professor of medicine, consultant, Division of Hematology/Oncology, Department of Internal Medicine, Mayo Clinic, discusses the role of transplant in patients with multiple myeloma.

Dennis R. Scribner, MD, FACOG, FACS, clinical associate professor for the University of Arizona School of Medicine, Arizona Oncology, discusses the use of chemotherapy in patients with ovarian cancer.

Malcolm Ross, MD, University of Pittsburgh, discusses unmet needs for patients with uterine carcinosarcoma.

Steven Coutre, MD, professor of medicine at Stanford University Medical Center, discusses combination strategies for the treatment of patients with acute lymphoblastic leukemia (ALL).

Kimberly L. Blackwell, MD, medical oncologist, Duke Cancer Institute, discusses the treatment of young women with breast cancer.

Tanios Bekaii-Saab, MD, professor of medicine, Mayo Clinic, discusses the potential of napabucasin, previously known as BBI-608, in patients with pancreatic cancer.

Frances Valdes-Albini, MD, assistant professor of clinical medicine, Sylvester Comprehensive Cancer Center, University of Miami Health System, discusses the FDA approval of adjuvant pertuzumab (Perjeta) in patients with HER2-positive breast cancer.

Sunil Verma, MD, professor and head of the Department of Oncology at the University of Calgary, medical director of the Tom Baker Cancer Centre, discusses emerging agents for the treatment of HER2-positive breast cancer.

Anees B. Chagpar, MD, FACS, associate professor, Department of Surgery, Yale School of Medicine, assistant director, Global Oncology, Yale Comprehensive Cancer Center, discusses surgery of the primary tumor in the metastatic setting of breast cancer.

Sarah B. Goldberg, MD, MPH, an assistant professor of medicine at the Yale School of Medicine and Yale Cancer Center, discusses sequencing after therapy with osimertinib (Tagrisso) in EGFR-positive non–small cell lung cancer.

Eleftherios (Terry) P. Mamounas, MD, medical director of the Comprehensive Breast Program at the University of Florida Health Cancer Center, discusses the management of neoadjuvant chemotherapy for patients with breast cancer.

Laurel W. Rice, MD, chair, Department of Obstetrics and Gynecology, University of Wisconsin School of Medicine and Public Health, discusses the importance of enrolling patients with gynecologic cancer on clinical trials.

Douglas A. Levine, MD, professor, Department of Obstetrics and Gynecology, director, Division of Gynecologic Oncology, NYU Langone's Perlmutter Cancer Center, discusses the randomized NRG Oncology Group 86P study for patients with endometrial cancer.

Snehal Bhoola, MD, assistant professor, Mercer University School of Medicine, associate professor, University of Arizona, Arizona Oncology, discusses enhanced recovery after surgery (ERAS) in gynecologic malignancies.

Toni Choueiri, MD, director, Lank Center for Genitourinary Oncology, director, Kidney Cancer Center, Jerome and Nancy Kohlberg Associate Professor of Medicine, Harvard Medical School, Dana-Farber Cancer Institute, discusses the latest treatments in genitourinary (GU) cancers.

Mike Janicek, MD, medical director, Genetics Division, Arizona Oncology, discusses progress with genetic testing in ovarian cancer.

Katherine Van Loon, MD, gastrointestinal cancer specialist, University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, discusses the management of rectal cancer.

Maha Hussain, MD, FACP, FASCO, Genevieve Teuton Professor of Medicine, Deputy Director, Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, discusses PARP inhibitors in the treatment of patients with prostate cancer.

Manish A. Shah, MD, director of gastrointestinal oncology and chief of Solid Tumor Service at Weill Cornell Medicine/NewYork-Presbyterian Hospital, discusses the relationship between helicobacter pylori (H. pylori) and immune response in gastric cancer.